Roche's risdiplam meets primary endpoint in trial of SMA drug in infants
January 23, 2020 at 01:18 AM EST
Roche's risdiplam met the primary endpoint in a pivotal clinical trial in infants with type 1 spinal muscular atrophy, the Swiss drugmaker said on Thursday.
